$81.52
-0.99 (-1.20%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LMAT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 3 observational
Held by 11 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, Qube Research & Technologies Ltd, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, +6 more) · FINRA short interest 5.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A PMCF Study to Confirm the Performance and Safety of the LeMaitre® TufTex Single Lumen Embolectomy CatheterNCT05386277Safety objective is defined as acceptable safety outcomes (e.g. (Serious) Device and/or Procedure Related Events) during the procedureOpen-label · Other | Not applicable | Recruiting | Device: TufTex Single Lumen Embolectomy Catheter | Arterial Thromboembolism | 112 | Jun 2027 | ≤ 315 d | 2024-10-18 |
| A PMCF Study Confirm the Performance and Safety of the TufTex Over-the-Wire (OTW) Embolectomy CathetersNCT05386342Performance objective is the technical success being <30% residual stenosisOpen-label · Treatment | Not applicable | Recruiting | Device: TufTex Over-the-Wire Embolectomy Catheter | Thrombus, Embolus, Occlusion; Vessel | 112 | Jun 2027 | ≤ 315 d | 2024-10-18 |
| Prospective and Non-randomized Registry of CardioCel 3DNCT04175327observationalIncidence of graft related reintervention | — | Active, not recruiting | Device: CardioCel implantation | Intracardiac and Septal Defects, Valve and Anulus Repair, Great Vessel Reconstruction, Peripheral Vessel Reconstruction, Suture Line Buttressing | 200 | Nov 2025 | — | 2025-03-10 |
| Evaluate Safety and Effectiveness of XenoSure® Biological Patch in the Application of Peripheral Vascular RepairNCT03173703Primary patency measured by ultrasoundRandomized · Single-masked · Treatment | Not applicable | Active, not recruiting | Device: Implant the XenoSure patch, Implant the Vascular-Patch · Procedure: Repair/reconstruction of the diseased vessel | Vascular Diseases | 144 | 2025-11-15 | — | 2025-03-10 |
| Post-Market Registry in Europe and US for the Use of VascuCelTMNCT04906824observationalIncidence of graft related reintervention | — | Active, not recruiting | Device: great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing | Great Vessel Reconstruction, Peripheral Vessel Reconstruction, Suture Line Buttressing | 100 | Oct 2025 | — | 2025-03-10 |
| LeMaitre LifeSpan® ePTFE Vascular Graft Retrospective RegistryNCT04620889observationalPercentage of vessels patent without requiring intervention to remain open | — | Completed | Device: AV Access, PVP | Diseased or Occluded Blood Vessels, Arteriovenous Shunting for Blood Access | 153 | 2023-11-24actual | — | 2024-10-18 |
| Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac RepairNCT03176225Leakage rate at 6 month post-procedure measured by ultrasoundRandomized · Single-masked · Treatment | Not applicable | Completed | Procedure: Open heart surgery to address the heart disease · Device: Close the defects with XenoSure Patch, Close the defects with Chest Polyester Patch | Heart Diseases | 142 | 2020-11-15actual | — | 2025-03-10 |
| Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access GraftsNCT00131872Primary or assisted primary patency at 1 yearOpen-label · Treatment | Phase 2 | Terminated | Device: Expedial Vascular Access Graft | End Stage Renal Disease | 172 | — | — | 2024-07-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19